These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

925 related articles for article (PubMed ID: 17213013)

  • 1. Cost-effectiveness of pregabalin for the management of neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia: a Canadian perspective.
    Tarride JE; Gordon A; Vera-Llonch M; Dukes E; Rousseau C
    Clin Ther; 2006 Nov; 28(11):1922-34. PubMed ID: 17213013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A cost-effectiveness comparison of desipramine, gabapentin, and pregabalin for treating postherpetic neuralgia.
    O'Connor AB; Noyes K; Holloway RG
    J Am Geriatr Soc; 2007 Aug; 55(8):1176-84. PubMed ID: 17661955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis of pregabalin versus gabapentin in the management of neuropathic pain due to diabetic polyneuropathy or post-herpetic neuralgia.
    Rodríguez MJ; Díaz S; Vera-Llonch M; Dukes E; Rejas J
    Curr Med Res Opin; 2007 Oct; 23(10):2585-96. PubMed ID: 17875242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pregabalin and gabapentin in matched patients with peripheral neuropathic pain in routine medical practice in a primary care setting: Findings from a cost-consequences analysis in a nested case-control study.
    Pérez C; Navarro A; Saldaña MT; Masramón X; Rejas J
    Clin Ther; 2010 Jul; 32(7):1357-70. PubMed ID: 20678683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pregabalin versus gabapentin in the management of peripheral neuropathic pain associated with post-herpetic neuralgia and diabetic neuropathy: a cost effectiveness analysis for the Greek healthcare setting.
    Athanasakis K; Petrakis I; Karampli E; Vitsou E; Lyras L; Kyriopoulos J
    BMC Neurol; 2013 Jun; 13():56. PubMed ID: 23731598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of a lidocaine 5% medicated plaster relative to gabapentin for postherpetic neuralgia in the United Kingdom.
    Dakin H; Nuijten M; Liedgens H; Nautrup BP
    Clin Ther; 2007 Jul; 29(7):1491-507. PubMed ID: 17825701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of a lidocaine 5% medicated plaster compared with gabapentin and pregabalin for treating postherpetic neuralgia: a german perspective.
    Liedgens H; Hertel N; Gabriel A; Nuijten M; Dakin H; Mitchell S; Nautrup BP
    Clin Drug Investig; 2008; 28(9):583-601. PubMed ID: 18666805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-utility of pregabalin as add-on to usual care versus usual care alone in the management of peripheral neuropathic pain in Belgium.
    Chevalier P; Lamotte M; Van Campenhout H; Eyckerman R; Annemans L
    J Med Econ; 2013; 16(5):596-605. PubMed ID: 23409950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparing healthcare costs of Medicaid patients with postherpetic neuralgia (PHN) treated with lidocaine patch 5% versus gabapentin or pregabalin.
    Kirson NY; Ivanova JI; Birnbaum HG; Wei R; Kantor E; Puenpatom RA; Ben-Joseph RH; Summers KH
    J Med Econ; 2010; 13(3):482-91. PubMed ID: 20684669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness analysis of a new 8% capsaicin patch compared to existing therapies for postherpetic neuralgia.
    Armstrong EP; Malone DC; McCarberg B; Panarites CJ; Pham SV
    Curr Med Res Opin; 2011 May; 27(5):939-50. PubMed ID: 21375358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A retrospective evaluation of the use of gabapentin and pregabalin in patients with postherpetic neuralgia in usual-care settings.
    Gore M; Sadosky A; Tai KS; Stacey B
    Clin Ther; 2007 Aug; 29(8):1655-70. PubMed ID: 17919547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Costs and health resources utilization following switching to pregabalin in individuals with gabapentin-refractory neuropathic pain: a post hoc analysis.
    Navarro A; Saldaña MT; Pérez C; Masramón X; Rejas J
    Pain Pract; 2012 Jun; 12(5):382-93. PubMed ID: 22004531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between pain relief and improvements in patient function/quality of life in patients with painful diabetic peripheral neuropathy or postherpetic neuralgia treated with pregabalin.
    Vinik A; Emir B; Cheung R; Whalen E
    Clin Ther; 2013 May; 35(5):612-23. PubMed ID: 23541708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost analysis of adding pregabalin or gabapentin to the management of community-treated patients with peripheral neuropathic pain.
    Sicras-Mainar A; Rejas-Gutiérrez J; Navarro-Artieda R; Planas-Comes A
    J Eval Clin Pract; 2012 Dec; 18(6):1170-9. PubMed ID: 21883712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Replacement of gabapentin with pregabalin in postherpetic neuralgia therapy.
    Ifuku M; Iseki M; Hidaka I; Morita Y; Komatus S; Inada E
    Pain Med; 2011 Jul; 12(7):1112-6. PubMed ID: 21692969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of pregabalin-mediated pain response by severity of sleep disturbance in patients with painful diabetic neuropathy and post-herpetic neuralgia.
    Vinik A; Emir B; Parsons B; Cheung R
    Pain Med; 2014 Apr; 15(4):661-70. PubMed ID: 24330406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 5% lidocaine medicated plaster versus pregabalin in post-herpetic neuralgia and diabetic polyneuropathy: an open-label, non-inferiority two-stage RCT study.
    Baron R; Mayoral V; Leijon G; Binder A; Steigerwald I; Serpell M
    Curr Med Res Opin; 2009 Jul; 25(7):1663-76. PubMed ID: 19485723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An economic evaluation of pregabalin versus usual care in the management of community-treated patients with refractory painful diabetic peripheral neuropathy in primary care settings.
    de Salas-Cansado M; Pérez C; Saldaña MT; Navarro A; González-Gómez FJ; Ruiz L; Rejas J
    Prim Care Diabetes; 2012 Dec; 6(4):303-12. PubMed ID: 22595032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost effectiveness of a lidocaine 5% medicated plaster compared with pregabalin for the treatment of postherpetic neuralgia in the UK: a Markov model analysis.
    Ritchie M; Liedgens H; Nuijten M
    Clin Drug Investig; 2010; 30(2):71-87. PubMed ID: 20067326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, controlled trial of oxycodone versus placebo in patients with postherpetic neuralgia and painful diabetic neuropathy treated with pregabalin.
    Zin CS; Nissen LM; O'Callaghan JP; Duffull SB; Smith MT; Moore BJ
    J Pain; 2010 May; 11(5):462-71. PubMed ID: 19962354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 47.